Selinexor in Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A clinical trial suggests efficacy and a manageable adverse event profile with selinexor for the treatment of relapsed or refractory DLBCL.
Lymphoma
Most Women Unaware of Breast Implant-Related Lymphoma
Even among women with breast implants, just over half have heard of BIA-ALCL.
T-Cell Lymphoblastic Lymphoma: Promising Results From Children’s Oncology Group AALL0434 Study
AALL0434, one of the largest prospective studies of T-LL, resulted in successful disease-free and overall survival outcomes.
Considerations for the Diagnostic Work-Up of Breast Implant–Associated Lymphoma
Flow cytometry may provide an efficient, sensitive, and specific tool for the differential diagnosis of breast implant–associated ALCL, but a cell block may be able to answer additional questions about the disease.
Addition of Rituximab to Chemotherapy for Pediatric High-Risk, Mature B-Cell NHL
For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.
Loss of Limb Mobility in a Patient With T-ALL Treated With Nelarabine
In this patient case, significant neurological adverse effects associated with nelarabine were noted at 30 days following initiation of therapy.
Xpovio Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
High-Intensity RIC-NMAC Regimen Associated With Greater Mortality Risk in Allogeneic Transplant NHL
High-intensity RIC-NMAC regimen Flu-Mel140, may be linked to higher nonrelapse mortality in patients with NHL undergoing allogeneic transplantation.
Tazverik Granted Accelerated Approval for Follicular Lymphoma
Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Timing of MD-MTX Prophylaxis for DLBCL CNS Relapse Evaluated
Administering MD-MTX prophylaxis against CNS relapse of DLBCL appeared best as early as possible or following R-CHOP completion.
-
Loading...
-
Loading...
Next post in Hematologic Cancers
